FLT3 and acute lymphoblastic leukemia: Seven patients (24.13%) with relapsed ALL underwent rigorous chemotherapy with FLAG preceded by a DLI, whereas the rest eight patients (27.58%) received a single-agent therapy such as HMAs, low-dose cytarabine, vincristine, and FLT3 inhibitors.